Similarly, relapsed or refractory patients with pre-B-cell acute lymphoblastic leukemia treated with CD22-CAR-T therapy after CD19-CAR failure often experience relapse due to a reduction in CD22 expression despite the persistence of CD22-CAR cells [62]. Here, CD22 is linked to B-cell acute lymphoblastic leukemia.